New Approaches to Dementia Heterogeneity

痴呆症异质性的新方法

基本信息

批准号：
10647902
负责人：
Gil Dan Rabinovici
金额：
$ 346.14万
依托单位：
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-05-01 至 2024-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10647902
关键词：
Acceleration Aging Alzheimer&apos s Disease American Award Basic Science Biological Biological Markers Biology Biometry Caregiver support Caring Chinese Clinical Clinical Trials Cognition Disorders Collaborations Collection Communities Creutzfeldt-Jakob Syndrome Data Dementia Diagnosis Diagnostic Disease Early Onset Alzheimer Disease Education Endowment Evaluation Film Foundations Frontotemporal Dementia Funding Generations Genetic Genomics Grant Heterogeneity Image Industry Collaboration International K-Series Research Career Programs Knowledge Latino Lead Leadership Medical Memory Minority Modeling Molecular Neurodegenerative Disorders Neurologic Neurologist Neurosciences Nurses Online Systems Pathologic Pathology Performance Physiological Policies Population Heterogeneity Process Progressive Supranuclear Palsy Proteomics Public Health Research Research Personnel Resources Sampling Science Scientist Site Specialist Specialized Center Tablets Talents Tauopathies Training United States National Institutes of Health Work brain health career catalyst clinical center clinical diagnostics clinical phenotype cohort community center corticobasal syndrome data management data sharing drug development education research ethnic diversity gender diversity health care delivery health economics health equity healthy aging improved innovation lectures normal aging novel novel strategies outreach programs recruit statistics symposium tau Proteins therapy development transcriptomics translational scientist

项目摘要

ABSTRACT The UCSF Alzheimer’s Disease Research Center (ADRC) is a major catalyst for a broad spectrum of dementia-related research conducted at UCSF and has served as a cornerstone for national and international multi-site diagnostic and treatment studies. In three previous cycles of funding under the P50 mechanism, we have organized a critical mass of dementia research and share our resources widely. We excel in clinical phenotyping, imaging, biospecimen collection, and pathologic evaluation of large and unique cohorts of early- onset AD (EOAD), frontotemporal dementia (FTD), progressive supranuclear palsy (PSP), corticobasal syndrome (CBS), Creutzfeldt-Jakob disease (CJD), and healthy controls. The ADRC supports and effectively leverages additional NIH and foundation funding, philanthropy, and industry collaborations to accomplish its aims. At the UCSF Memory and Aging Center alone, ADRC clinical cohorts, data, and biosamples are currently utilized by 26 R grants, 6 K awards, 4 U grants, and 38 non-NIH grants. Projects and pilot awards have helped launch young investigator careers and major research programs. ADRC data and biosamples are utilized extensively by other ADRCs and an extensive network of collaborators. In this new P30 application, we accelerate efforts to define subtypes of healthy aging, MCI, AD, FTD, PSP, CBS, and CJD that predict specific molecular and physiological causes for dementia, improve early recognition and tracking of transitions from normal aging to dementia, and stimulate drug development and clinical trials. The ADRC will consist of seven cores: Administrative, Clinical, Data Management and Statistics, Pathology, Outreach Recruitment and Engagement, Imaging, and Biomarker and a Research Education Component. These cores will work collectively to pursue the following overarching specific aims: Aim 1: Explore the heterogeneous features of healthy aging, MCI, AD, FTD-spectrum disorders, and CJD to better understand their clinical, genetic, and molecular underpinnings. Aim 2: Leverage the valuable cohorts in the ADRC and the talented neuroscience communities at UCSF and beyond to “enhance the performance of innovative research” around diagnosis and treatment of dementia. Aim 3: Increase understanding of the unique cultural and biological features of aging Chinese and Latino Americans, while educating these communities with outreach lectures and web-based presentations. Aim 4: Develop innovative approaches to data management and biostatistics to support easy access and analysis of ADRC-related data while offering statistical support to our investigators. Aim 5: Train new leaders in dementia research with innovative education approaches and educate medical and lay communities about the heterogeneity of dementia with conferences, web-based presentations, and films. Aim 6: Create a new Biomarker Core to enhance the genomic, proteomic, and transcriptomic data captured from our extensive biospecimen collection. Aim 7: Transition to a more gender and ethnically diverse ADRC leadership by 2024.

抽象的 UCSF阿尔茨海默氏病研究中心（ADRC）是广泛的催化剂在UCSF进行的与痴呆有关的研究，并一直是国家和国际的基石多站点诊断和治疗研究。在P50机制下以前的三个资金周期中，我们已经组织了大量的痴呆症研究，并广泛分享我们的资源。我们在临床方面表现出色表型，成像，生物测量收集和病理评估发作AD（EOAD），额颞痴呆（FTD），进行性超胸骨麻痹（PSP），皮质果实综合征（CBS），Creutzfeldt-Jakob病（CJD）和健康对照。 ADRC支持并有效利用其他NIH和基金会资金，慈善事业和行业合作来实现其目标。仅在UCSF内存和老化中心，ADRC临床人群，数据和生物样本是由26 R赠款，6 k奖，4个U赠款和38个非NIH赠款使用。项目和飞行员奖有助于启动年轻的研究者职业和主要研究计划。使用ADRC数据和生物样本其他ADRC和广泛的合作者网络广泛。在这项新的P30应用中，我们加快了定义健康衰老的亚型，MCI，AD，FTD，PSP， CBS和CJD预测特定的分子和物理痴呆原因，改善了早期识别并跟踪从正常衰老到痴呆症的过渡，并刺激药物发育和临床试验。 ADRC将由七个核心组成：行政，临床，数据管理和统计，病理学，外展招聘和参与，成像以及生物标志物以及研究教育部分。这些核心将共同努力追求以下总体特定目的：目标1：探索异质健康衰老，MCI，AD，FTD谱系障碍和CJD的特征，以更好地了解其临床，遗传，和分子基础。目标2：利用ADRC和才华横溢的神经科学中的宝贵人群 UCSF及其以外的社区，以“增强诊断和治疗痴呆症。目标3：提高对衰老独特文化和生物学特征的了解中国和拉丁裔美国人，同时通过宣传讲座和基于网络教育这些社区演讲。目标4：开发创新的方法来进行数据管理和生物统计学以支持简单访问和分析与ADRC相关的数据，同时向我们的研究人员提供统计支持。目标5：火车痴呆症研究的新领导者采用创新的教育方法，教育医学和外行关于痴呆症的异质性，基于网络的演示和电影的异质性。目标6：创建一个新的生物标志物核心，以增强从中捕获的基因组，蛋白质组学和转录组数据我们广泛的生物测量系列。目标7：过渡到更加性别和种族化的ADRC 到2024年的领导。